MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants

MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants

Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and mod...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sua Lee, Shina Jang, Jihoon Kang, Soo Bin Park, Young Woo Han, Hyemi Nam, Munkyung Kim, Jeewon Lee, Ki Joon Cho, Jeonghun Kim, Miyoung Oh, Jihye Ryu, Jong Hyeon Seok, Yunhwa Kim, Jee-Boong Lee, Man-Seong Park, Yong-Sung Kim, Hosun Park, Dong-Sik Kim
Format: article
Langue:EN
Publié: Frontiers Media S.A. 2021
Sujets:
MG1141A
SARS-CoV-2
monoclonal antibody
outbreak
spike protein
Immunologic diseases. Allergy
RC581-607
Accès en ligne:https://doaj.org/article/7e740e1bfe9248e3844839c81b27bd6d
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/7e740e1bfe9248e3844839c81b27bd6d

Documents similaires